Andrew McGrath

Kings Health Partners

Papers

1

Total Citations

62

H-Index

1

About

Andrew McGrath is a urological researcher whose work has made meaningful contributions to the management of small renal cell carcinoma (RCC), one of the most common kidney malignancies encountered in clinical practice. His most cited work, a 2016 retrospective comparative study conducted at a high-volume tertiary centre, rigorously examined the oncologic outcomes of percutaneous radiofrequency ablation (RFA) versus robotic-assisted partial nephrectomy (RPN) for T1 stage renal cell carcinoma — a clinically significant question given the growing prevalence of incidentally detected small renal masses. This study has accumulated 62 citations, reflecting its relevance to urologists and oncologists navigating treatment decisions for early-stage kidney cancer. By directly comparing a minimally invasive ablative technique with a sophisticated robotic surgical approach, McGrath and his colleagues provided clinicians with valuable real-world evidence to guide individualized patient care. His research sits at the intersection of surgical oncology and interventional urology, addressing the ongoing debate between nephron-sparing surgery and ablative therapies. His contributions have helped shape contemporary guidelines and informed the evolving standard of care for patients with localized renal tumours.

Research Focus

Key Achievements

1
H-Index
1
Papers
62
Total Citations
62
Avg Citations/Paper
🏆 Most Cited Paper
Percutaneous Radiofrequency Ablation Versus Robotic-Assisted Partial Nephrectomy for the Treatment of Small Renal Cell Carcinoma
62 citations · 2016
📈 Most Prolific Year: 2016 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Kings Health Partners

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago